Trevi Therapeutics TRVI
$13.35 −$0.37 (-2.70%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $13.35 0.00%
Open$13.58
Prev close$13.72
Day range$13.23 – $13.90
Volume2.09M
Market cap$1.90B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$24.49M-76.0% YoY
Net profit-$21.45M-81.8% YoY
Diluted EPS-$0.13-62.5% YoY
Free cash flow-$19.71M-81.0% YoY
Operating cash flow-$19.69M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-24.7%
Return on assets-23.8%
Return on invested capital-28.4%
Current ratio38.86
Liabilities / assets2.6%
Cash & investments$299.41M
Total debt$187,000.00
Net cash (debt)$299.22M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $24.49M | $20.51M | $14.91M | $49.33M | $10.22M |
| Selling and Admin Expenses | $5.42M | $5.36M | $4.97M | $15.85M | $4.03M |
| -General & Admin Expense | $5.42M | $5.36M | $4.97M | $15.85M | $4.03M |
| Research & Development | $19.06M | $15.15M | $9.94M | $33.48M | $6.19M |
| Operating Profit | -$24.49M | -$20.51M | -$14.91M | -$49.33M | -$10.22M |
| Net Non-Operating Interest Income (Expense) | $3.02M | $2.70M | $1.70M | $6.54M | $1.90M |
| Non-Operating Interest Income | $3.02M | $2.70M | $1.70M | $6.54M | $1.90M |
| Other Income (Expense) | -$3,000.00 | -$3,000.00 | $4,000.00 | -$31,000.00 | -$15,000.00 |
| Other Non-Operating Income (Expenses) | -$3,000.00 | -$3,000.00 | $4,000.00 | -$31,000.00 | -$15,000.00 |
| Pretax Profit | -$21.47M | -$17.82M | -$13.21M | -$42.82M | -$8.33M |
| Tax | -$19,000.00 | -$19,000.00 | -$20,000.00 | -$64,000.00 | -$16,000.00 |
| Net Profit | -$21.45M | -$17.80M | -$13.19M | -$42.76M | -$8.32M |
| Profit from Continuing Operations | -$21.45M | -$17.80M | -$13.19M | -$42.76M | -$8.32M |
| Net Income to Parent Company | -$21.45M | -$17.80M | -$13.19M | -$42.76M | -$8.32M |
| Net Income to Common Stockholders | -$21.45M | -$17.80M | -$13.19M | -$42.76M | -$8.32M |
| Basic EPS | -$0.13 | -$0.11 | -$0.09 | -$0.32 | -$0.06 |
| Diluted EPS | -$0.13 | -$0.11 | -$0.09 | -$0.32 | -$0.06 |
| Non-Operating Interest Expense | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $310.81M | $330.52M | $179.61M | $193.44M | $193.44M |
| Total Current Assets | $305.80M | $325.71M | $176.12M | $191.66M | $191.66M |
| Cash and Cash Equivalents & Short-Term Investments | $299.41M | $318.87M | $171.78M | $188.26M | $188.26M |
| -Cash and Cash Equivalents | $27.85M | $54.30M | $19.41M | $18.91M | $18.91M |
| -Short Term Investments | $271.56M | $264.57M | $152.37M | $169.35M | $169.35M |
| Prepaid Assets | $3.58M | $4.26M | $2.22M | $1.26M | $1.26M |
| Other Current Assets | $2.81M | $2.57M | $2.12M | $2.13M | $2.13M |
| Total Non-Current Assets | $5.02M | $4.81M | $3.49M | $1.78M | $1.78M |
| Net PPE | $813,000.00 | $878,000.00 | $875,000.00 | $855,000.00 | $855,000.00 |
| -Gross PPE | $813,000.00 | $878,000.00 | $875,000.00 | $1.21M | $1.21M |
| Other Non-Current Assets | $4.20M | $3.94M | $2.61M | $928,000.00 | $928,000.00 |
| Total Liabilities | $8.06M | $9.01M | $7.48M | $10.20M | $10.20M |
| Total Current Liabilities | $7.87M | $8.74M | $7.12M | $9.75M | $9.75M |
| Payables | $1.51M | $3.10M | $2.22M | $3.91M | $3.91M |
| -Accounts Payable | $1.51M | $3.10M | $2.22M | $3.91M | $3.91M |
| Current Accrued Expenses | $3.53M | $3.21M | $3.31M | $2.79M | $2.79M |
| Short-Term Debt and Capital Lease Obligation | $340,000.00 | $329,000.00 | $318,000.00 | $307,000.00 | $307,000.00 |
| -Current Capital Lease Obligation | $340,000.00 | $329,000.00 | $318,000.00 | $307,000.00 | $307,000.00 |
| Total Non-Current Liabilities | $187,000.00 | $276,000.00 | $364,000.00 | $446,000.00 | $446,000.00 |
| Long Term Debt and Capital Lease Obligation | $187,000.00 | $276,000.00 | $364,000.00 | $446,000.00 | $446,000.00 |
| -Long Term Capital Lease Obligation | $187,000.00 | $276,000.00 | $364,000.00 | $446,000.00 | $446,000.00 |
| Total Equity | $302.76M | $321.51M | $172.13M | $183.24M | $183.24M |
| Stockholders' Equity | $302.76M | $321.51M | $172.13M | $183.24M | $183.24M |
| Capital Stock | $143,000.00 | $142,000.00 | $128,000.00 | $128,000.00 | $128,000.00 |
| -Common Stock | $143,000.00 | $142,000.00 | $128,000.00 | $128,000.00 | $128,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $686.36M | $682.58M | $515.19M | $512.77M | $512.77M |
| Retained Earnings | -$382.25M | -$360.79M | -$343.00M | -$329.80M | -$329.80M |
| Gains/Losses Not Affecting Retained Earnings | -$1.50M | -$425,000.00 | -$190,000.00 | $148,000.00 | $148,000.00 |
| -Accumulated Depreciation | – | – | – | -$359,000.00 | -$359,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$19.69M | -$17.43M | -$16.69M | -$42.09M | -$7.63M |
| Net cash flow from continuing operations | -$19.69M | -$17.43M | -$16.69M | -$42.09M | -$7.63M |
| Net Income from Continuing Operations | -$21.45M | -$17.80M | -$13.19M | -$42.76M | -$8.32M |
| Depreciation & Depletion & Amortization | $41,000.00 | $34,000.00 | $34,000.00 | $144,000.00 | $31,000.00 |
| Other Non-Cash Items | $101,000.00 | $102,000.00 | $105,000.00 | $463,000.00 | $133,000.00 |
| Change in Working Capital | -$829,000.00 | -$2.52M | -$5.40M | -$3.49M | -$274,000.00 |
| -Change in Prepaid Assets | -$994,000.00 | -$2.93M | -$2.84M | -$1.48M | $158,000.00 |
| -Change in Payables and Accrued Expense | $165,000.00 | $409,000.00 | -$2.56M | -$2.01M | -$432,000.00 |
| Net cash flow from investing | -$7.18M | -$112.04M | $16.97M | -$94.11M | -$30.61M |
| Net Cash Flow from Continuing Investing Activities | -$7.18M | -$112.04M | $16.97M | -$94.11M | -$30.61M |
| Net PPE Purchase and Sale | -$25,000.00 | -$124,000.00 | -$102,000.00 | -$12,000.00 | $0.00 |
| Net Investment Purchase and Sale | -$7.15M | -$111.91M | $17.07M | -$94.10M | -$30.61M |
| Financing Cash Flow | $412,000.00 | $164.36M | $222,000.00 | $121.01M | $284,000.00 |
| Net Cash Flow from Continuing Financing Activities | $412,000.00 | $164.36M | $222,000.00 | $121.01M | $284,000.00 |
| Net Issuance Payments Of Debt | $0.00 | $0.00 | $0.00 | -$11,000.00 | $0.00 |
| Net Common Stock Issuance | $0.00 | – | – | $108.15M | $0.00 |
| Proceeds from Stock Option Exercised | $411,000.00 | $1.79M | $222,000.00 | $12.95M | $284,000.00 |
| Net Other Financing Charges | $1,000.00 | – | – | -$84,000.00 | $0.00 |
| Ending Cash Balance | $27.85M | $54.30M | $19.41M | $18.91M | $18.91M |
| Net Change in Cash | -$26.45M | $34.89M | $498,000.00 | -$15.18M | -$37.96M |
| Beginning Cash Balance | $54.30M | $19.41M | $18.91M | $34.10M | $56.87M |
| Free Cash Flow | -$19.71M | -$17.55M | -$16.79M | -$42.10M | -$7.63M |
| Gain/Loss from Continuing Operations | – | – | – | $7,000.00 | – |
No comments yet — be the first to weigh in on TRVI.
Sign in to join the discussion.